



## **Cover Letter - Cingal 16-02 Statistical Analysis Plan for Protocol Version 4.0**

**A Randomized, Double-Blind, Active Comparator Controlled, Multi-Center  
Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined  
with Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief  
of Osteoarthritis of the Knee**

**NCT # 03191903**

**Date of SAP: 14 December 2017**

## Statistical Analysis Plan

**A Randomized, Double-Blind, Placebo Controlled,  
Multi-Center Study of a Single Injection Cross-  
Linked Sodium Hyaluronate Combined with  
Triamcinolone Hexacetonide (Cingal™) to Provide  
Symptomatic Relief of Osteoarthritis of the Knee**

**Protocol Number: CINGAL 16-02 Version 4.0**



**Protocol Issue Date: 05 Dec2017**


**SAP Date: 14 Dec2017**

**Anika Therapeutics, Inc.**

Prepared by: Gary Stevens, Ph.D.  
DynaStat Consulting, Inc.

Approved by:

  
  
Anika Therapeutics, Inc. 21 Dec 2017

Gary Stevens, Ph.D.  
  
DynaStat Consulting, Inc. 21 Dec 2017

## Statistical Analysis Plan

**A Randomized, Double-Blind, Placebo Controlled,  
Multi-Center Study of a Single Injection Cross-  
Linked Sodium Hyaluronate Combined with  
Triamcinolone Hexacetonide (Cingal™) to Provide  
Symptomatic Relief of Osteoarthritis of the Knee**

**Protocol Number: CINGAL 16-02 Version 4.0**

**Protocol Issue Date: 05 Dec2017**

**SAP Date:14 Dec2017**

**Anika Therapeutics, Inc.**

Prepared by: Gary Stevens, Ph.D.  
DynaStat Consulting, Inc.

Approved by:

\_\_\_\_\_

\_\_\_\_\_  
Gary Stevens, Ph.D.

\_\_\_\_\_  
Anika Therapeutics, Inc.

\_\_\_\_\_  
Dynastat Consulting, Inc.

## Table of Contents

### Contents

Table of Contents .....	2
1.0 Introduction.....	3
2.0 Study Design.....	3
3.0 Objectives .....	4
3.1 Primary Efficacy Endpoint .....	4
3.2 Secondary Efficacy Endpoints.....	4
3.3 Exploratory Endpoints .....	5
3.4 Safety Endpoint.....	5
4.0 Statistical Methods in Protocol .....	6
4.1 Statistical Methods.....	6
4.1.1 Sample Size.....	6
4.1.2 Primary Efficacy Endpoint .....	6
4.1.3 Secondary Efficacy Endpoints.....	8
4.1.4 Exploratory Endpoints .....	12
4.2 Statistical Methods.....	13
4.3 Demographic and Baseline Characteristics .....	13
4.4 Adverse Events .....	13
4.5 Subject Populations.....	14
4.6 Additional Analyses.....	14

## 1.0 Introduction

This document presents the statistical analysis plan (SAP) for the Anika Therapeutics, Inc. protocol Cingal 16-02. This incorporates the data listings, summary tables, and statistical analyses. This document is based on the original final protocol and case report forms (CRFs).

## 2.0 Study Design

This is a multi-center, randomized, double-blind, parallel group, active comparator controlled trial to evaluate the efficacy and safety of a single injection of Cingal for the relief of joint pain in subjects with OA of the knee.

Subjects with OA defined as Kellgren-Lawrence (K-L) I-III in the index knee will be eligible for this study. Felson, et al 2004<sup>1</sup>, encouraged the use of both OA symptoms and radiographic changes in the assessment of OA. This study will employ both methods to screen subjects. Structural severity will be evaluated with the K-L classification score, a composite index of the presence and severity of joint space narrowing, osteophytes, sclerosis, deformity and cysts

For the evaluation of symptomatic severity, two main domains are important. The first is pain and the second is functional impairment. Other domains often used include subject's overall assessment, ROM and performance. Domains identified by OMERACT as core variables to be used in clinical trials involving OA are pain, function and the Patient Global Assessment which will be captured as part of this study.

Baseline and post-treatment pain, physical function and stiffness will be measured using the WOMAC questionnaire. Range of Motion, Patient and Evaluator Global Assessment and the EuroQol will be used to assess symptomatic severity throughout the study. In addition, the number of acetaminophen/paracetamol pills taken will be captured as an indirect measure of pain and will be done at each visit.

Subjects meeting the inclusion/exclusion criteria will be randomized to receive a single injection of Cingal, Monovisc or triamcinolone hexacetonide (TH) in the index knee. Since there is a difference in volume between Cingal, Monovisc and TH, the treating physician will not be considered blinded. To maintain the double-blind design of the study, there will be a person assigned to the role of Treating Physician and one person assigned to the role of Blinded Evaluator. The Treating Physician, most often the PI, will administer the injection but will not participate in the evaluation of study treatment effectiveness. A second individual, designated as the Blinded Evaluator, is blinded to treatment and will complete the pre- and post-treatment Evaluator Global Assessment, knee exams and ROM measurements. To maintain the subject blinding, the injection syringe will be prepared separate from the patient and the injection will be masked from the subject.

---

<sup>1</sup> Felson, DT, Nevitt MC. Epidemiologic studies for osteoarthritis: new versus conventional study design approaches. Rheumatic Diseases Clinics of North America 2004. 30(4):783-97.

The subject will be trained on how to complete the WOMAC, Patient Global Assessment and EuroQol. The subject should complete these questionnaires prior to any physical evaluation that must be done at each follow-up visit.

The Blinded Evaluator will collect and record AEs from the subjects and consult the Treating Physician only as needed in the management of AEs. The Blinded Evaluator will be a physician, research nurse, registered physiotherapist or physician assistant trained to perform the assessments outlined in the protocol.

Up to 40 sites in Europe may participate in the study to enroll 576 subjects. Subject participation will last approximately 7 months with follow-up visits scheduled at weeks 1, 3, 6, 12, 18, and 26 after the treatment injection.

### 3.0 Objectives

The objective of this study is to evaluate the efficacy and safety of a single injection of Cingal for relief of joint pain in subjects with OA of the knee who have not responded to conservative treatment (weight reduction, physical therapy, pain medications, etc.).

#### 3.1 PRIMARY EFFICACY ENDPOINT

- The change from baseline in knee pain as measured by the WOMAC Pain Score (100 mm VAS) at 26 weeks post treatment comparing the Cingal group to the Triamcinolone Hexacetonide (TH) group.

#### 3.2 SECONDARY EFFICACY ENDPOINTS

- The change from baseline in knee pain as measured by the WOMAC Pain Score (100 mm VAS) at 3 weeks post treatment comparing the Cingal group to the Monovisc group.
- The responder rate as identified by the Outcomes Measures for Rheumatic Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) responder index at 26 weeks post treatment comparing the Cingal group to the TH group.
- The change from baseline in WOMAC Physical Function score at 26 weeks post treatment comparing the Cingal group to the TH group.
- The change from baseline in WOMAC Stiffness score at 26 weeks post treatment comparing the Cingal group to the TH group.
- The change from baseline in Total WOMAC score at 26 weeks post treatment comparing the Cingal group to the TH group.
- The change from baseline in the Patient Global Assessment at 26 weeks post treatment in the Cingal group compared to the TH group.
- The change from baseline in the Evaluator Global Assessment at 26 weeks post treatment in the Cingal group compared to the TH group.
- The change from baseline in knee pain as measured by the WOMAC Pain Score (100 mm VAS) at 1 week post treatment comparing the Cingal group and the Monovisc group.
- The usage of rescue medication through 26 weeks post treatment in the Cingal group

compared to the TH group.

### *3.3 EXPLORATORY ENDPOINTS*

Any comparisons between groups (Cingal, Monovisc, TH), within groups and / or time points (from baseline through to 26 weeks) not described in the primary or secondary endpoints may be presented in the exploratory endpoints including:

- EuroQol (EQ-5D)
- WOMAC Pain Score (100mm VAS)
- OMERACT-OARSI
- Total WOMAC
- WOMAC Stiffness Score
- WOMAC Physical Function
- Patient Global Assessment
- Evaluator Global Assessment
- Range of Motion
- Rescue Medication Usage
- Number of Treatment Failures due to Additional Procedure or Use of Disallowed Medication

### *3.4 SAFETY ENDPOINT*

The incidence, timing, severity, and relationship to treatment of all Adverse Events (AE) will be collected and coded using Medical Dictionary for Regulatory Activities (MedDRA). Local injection site and non-local events will be recorded separately.

## 4.0 Statistical Methods in Protocol

### 4.1 STATISTICAL METHODS

This Statistical Analysis Plan provides the details of the statistical analysis of the study data that is described in the protocol.

#### 4.1.1 Sample Size

The primary comparison in the study will be between Cingal and triamcinolone hexacetonide with respect to the difference in the change in the WOMAC pain score from baseline at 26 weeks after study injection.

It is assumed that the difference in the mean responses for Cingal and triamcinolone hexacetonide at 26 weeks would be 10 mm based on previous clinical trials of similar viscosupplementation products and the Cingal 13-01 trial with a standard deviation of 20. The sample size calculation is based upon a t-test. The sample size that is necessary to detect that specified difference at a power of 90% with a significance level of 5% in a 2:1 enrollment ratio is 128 in the Cingal group and 64 in the triamcinolone hexacetonide group. If a 15% drop out rate is assumed then enrolling in a 24:4:1 (Cingal: Monovisc :triamcinolone hexacetonide ratio) a total of 576 evaluable subjects, 256 subjects in the Cingal arm, 256 subjects in the Monovisc arm and 64 subjects in the triamcinolone hexacetonide arm is needed. This will provide 90% power to detect the difference between Cingal compared to triamcinolone hexacetonide at 26 weeks at a 5% significance level.

#### 4.1.2 Primary Efficacy Endpoint

**4.1.2.1 The primary efficacy endpoint is the change from baseline in knee pain as measured by the WOMAC Pain Score (100 mm VAS) at 26 weeks post treatment comparing the Cingal group to the triamcinolone hexacetonide (TH) group.**

Data will be analyzed via an analysis of variance (ANOVA) with a term for treatment and baseline pain score as a covariate. The primary hypothesis will be tested by a predefined contrast for comparing the Cingal group to the triamcinolone hexacetonide group. Formally, the hypothesis to be tested is:

$$H_0: \mu_{DC} = \mu_{DT} \text{ versus } H_A: \mu_{DC} \neq \mu_{DT}.$$

Where  $\mu_{DC}$  is the mean change from baseline in the WOMAC Pain Score for the Cingal group at 26 weeks and  $\mu_{DT}$  is the mean change from baseline in the WOMAC Pain Score for the triamcinolone hexacetonide group at 26 weeks. Since there are three treatment groups in this study, this hypothesis will be tested using a one way ANOVA and constructing a contrast for this hypothesis. This process is the same as using a baseline pain adjusted two-sample t-test with the common variance estimate from the ANOVA.

The anticipated SAS code for this analysis is given as:



The mean difference will be estimated and tested using the contrasts from PROC GLM on the responses at the 26 week time period.

```
PROC GLM DATA=EFF;
  WHERE VISITNO = 26;
  CLASS TRT;
  MODEL WOMDIFF = BASEWOM TRT / TYPE3 ALPHA=0.05;
  ESTIMATE 'CINGAL VS MONOVISC' TRT 1 -1 0 ;
  ESTIMATE 'CINGAL VS TH'      TRT 1 0 -1 ;
  ESTIMATE 'MONOVISC VS TH'    TRT 0 1 -1 ;
  LSMEANS TRT / DIFF CL ALPHA=0.05;
  FORMAT TRT TRTF. ;
RUN;
```

In this model, the WOMDIFF is the difference in WOMAC Pain Scores from baseline. The variable TRT is a categorical variable where 1 = Cingal, 2=Monovisc, and 3=TH. The variable BASEWOM is the baseline WOMAC scores and the variable VISITNO is the visit number identifier. ODS statements will be used to output the contrasts and the mean differences into data sets that can be easily displayed using PROC REPORT. The primary analysis will be comparing Cingal to TH.

The tables for this analysis will be displayed as:

#### Summary of Least Squares Means at 26 weeks – WOMAC Pain Score

Treatment Group	Mean Percent Improvement LS Mean	Standard Error
Cingal		
Monovisc		
TH		

#### Summary of Differences in Mean Responses at 26 Weeks – WOMAC Pain Score

Treatment Group	Mean Percent Improvement	Standard Error	Lower Confidence Limit	Upper Confidence Limit	p-value
Cingal – Monovisc					
Cingal – TH (Primary)					
Monovisc - TH					

### 4.1.3 Secondary Efficacy Endpoints

#### 4.1.3.1 The change from baseline in knee pain as measured by the WOMAC Pain Score (100 mm VAS) at 3 weeks post treatment comparing the Cingal group to the Monovisc group.

Data will be analyzed via an analysis of variance with a term for treatment and baseline pain score as a covariate. The primary hypothesis will be tested by a predefined contrast for comparing the Cingal group to the triamcinolone hexacetonide group. Formally, the hypothesis to be tested is:

$$H_0: \mu_{DC} = \mu_{DT} \text{ versus } H_A: \mu_{DC} \neq \mu_{DT}$$

Where  $\mu_{DC}$  is the mean change from baseline in the WOMAC Pain Score for the Cingal group at 3 weeks and  $\mu_{DT}$  is the mean change from baseline in the WOMAC Pain Score for the Monovisc group at 3 weeks. Since there are three treatment groups in this study, this hypothesis will be tested using a one way ANOVA and constructing a contrast for this hypothesis. This process of constructing a contrast is the same as using a two-sample t-test with the common variance estimate from the ANOVA.

This will be analyzed and tables like the primary endpoint in section 4.1.2.1.

#### 4.1.3.2 The responder rate as identified by the OMERACT-OARSI responder index at 26 weeks post treatment comparing the Cingal group to the triamcinolone hexacetonide group.

The response rate for the Cingal group and Triamcinolone Hexacetonide (TH) group will be calculated and tested using Fisher's exact test. Formally, the hypothesis to be tested is:

$$H_0: \pi_C = \pi_T \text{ versus } H_0: \pi_C \neq \pi_T$$

Where  $\pi_C$  is the responder rate for the Cingal group and  $\pi_T$  is the responder rate for the triamcinolone hexacetonide group.

This will be estimated and tested using PROC FREQ with the EXACT option. The results will be displayed similar to:

#### Summary of the OMERACT-OARSI Responder Rates at 26 Weeks

Parameter	Cingal	Monovisc	TH
Estimate n/N (%)			
Cingal vs TH (Primary) (p-value)			
Cingal vs Monovisc (p-value)			
Monovisc vs TH (p-value)			

**4.1.3.3 The change from baseline in WOMAC Physical Function score at 26 weeks post treatment comparing the Cingal group to the triamcinolone hexacetonide group.**

Data will be analyzed via an analysis of variance (ANOVA) with a term for treatment and baseline function score as a covariate. The primary hypothesis will be tested by a predefined contrast for comparing the Cingal group to the triamcinolone hexacetonide group. Formally, the hypothesis to be tested is:

$$H_0: \mu_{DC} = \mu_{DT} \text{ versus } H_A: \mu_{DC} \neq \mu_{DT}.$$

Where  $\mu_{DC}$  is the mean change from baseline in the WOMAC Function Score for the Cingal group at 26 weeks and  $\mu_{DT}$  is the mean change from baseline in the WOMAC Function Score for the triamcinolone hexacetonide group at 26 weeks. Since there are three treatment groups in this study, this hypothesis will be tested using a one way ANOVA and constructing a contrast for this hypothesis. This process is the same as using a baseline function adjusted two-sample t-test with the common variance estimate from the ANOVA.

This will be analyzed and tables like the primary endpoint in section 4.1.2.1.

**4.1.3.4 The change from baseline in WOMAC Stiffness score at 26 weeks post treatment comparing the Cingal group to the triamcinolone hexacetonide group.**

Data will be analyzed via an analysis of variance (ANOVA) with a term for treatment and baseline stiffness score as a covariate. The primary hypothesis will be tested by a predefined contrast for comparing the Cingal group to the triamcinolone hexacetonide group. Formally, the hypothesis to be tested is:

$$H_0: \mu_{DC} = \mu_{DT} \text{ versus } H_A: \mu_{DC} \neq \mu_{DT}.$$

Where  $\mu_{DC}$  is the mean change from baseline in the WOMAC Stiffness Score for the Cingal group at 26 weeks and  $\mu_{DT}$  is the mean change from baseline in the WOMAC Stiffness Score for the triamcinolone hexacetonide group at 26 weeks. Since there are three treatment groups in this study, this hypothesis will be tested using a one way ANOVA and constructing a contrast for this hypothesis. This process is the same as using a baseline Stiffness adjusted two-sample t-test with the common variance estimate from the ANOVA.

This will be analyzed and tables like the primary endpoint in section 4.1.2.1.

**4.1.3.5 The change from baseline in Total WOMAC score at 26 weeks post treatment comparing the Cingal group to the triamcinolone hexacetonide group.**

Data will be analyzed via an analysis of variance (ANOVA) with a term for treatment and baseline Total WOMAC score as a covariate. The primary hypothesis will be tested by a predefined

contrast for comparing the Cingal group to the triamcinolone hexacetonide group. Formally, the hypothesis to be tested is:

$$H_0: \mu_{DC} = \mu_{DT} \text{ versus } H_A: \mu_{DC} \neq \mu_{DT}.$$

Where  $\mu_{DC}$  is the mean change from baseline in the Total WOMAC Score for the Cingal group at 26 weeks and  $\mu_{DT}$  is the mean change from baseline in the Total WOMAC Score for the triamcinolone hexacetonide group at 26 weeks. Since there are three treatment groups in this study, this hypothesis will be tested using a one way ANOVA and constructing a contrast for this hypothesis. This process is the same as using a baseline Total WOMAC adjusted two-sample t-test with the common variance estimate from the ANOVA.

This will be analyzed and tables like the primary endpoint in section 4.1.2.1.

**4.1.3.6 The change from baseline in the Patient Global Assessment at 26 weeks post treatment comparing the Cingal group to the triamcinolone hexacetonide group.**

Data will be analyzed via an analysis of variance (ANOVA) with a term for treatment and baseline PGA score as a covariate. The primary hypothesis will be tested by a predefined contrast for comparing the Cingal group to the triamcinolone hexacetonide group. Formally, the hypothesis to be tested is:

$$H_0: \mu_{DC} = \mu_{DT} \text{ versus } H_A: \mu_{DC} \neq \mu_{DT}.$$

Where  $\mu_{DC}$  is the mean change from baseline in the PGA for the Cingal group at 26 weeks and  $\mu_{DT}$  is the mean change from baseline in the PGA for the triamcinolone hexacetonide group at 26 weeks. Since there are three treatment groups in this study, this hypothesis will be tested using a one way ANOVA and constructing a contrast for this hypothesis. This process is the same as using a baseline PGA adjusted two-sample t-test with the common variance estimate from the ANOVA.

This will be analyzed and tables like the primary endpoint in section 4.1.2.1.

**4.1.3.7 The change from baseline in the Evaluator Global Assessment at 26 weeks post treatment comparing the Cingal group to the triamcinolone hexacetonide group.**

Data will be analyzed via an analysis of variance (ANOVA) with a term for treatment and baseline EGA score as a covariate. The primary hypothesis will be tested by a predefined contrast for comparing the Cingal group to the triamcinolone hexacetonide group. Formally, the hypothesis to be tested is:

$$H_0: \mu_{DC} = \mu_{DT} \text{ versus } H_A: \mu_{DC} \neq \mu_{DT}.$$

Where  $\mu_{DC}$  is the mean change from baseline in the EGA for the Cingal group at 26 weeks and  $\mu_{DT}$  is the mean change from baseline in the EGA for the triamcinolone hexacetonide group at 26 weeks. Since there are three treatment groups in this study, this hypothesis will be tested using a one way ANOVA and constructing a contrast for this hypothesis. This process is the same as using a baseline EGA adjusted two-sample t-test with the common variance estimate from the ANOVA.

This will be analyzed and tables like the primary endpoint in section 4.1.2.1.

#### **4.1.3.8 The change from baseline in knee pain as measured by the WOMAC Pain Score (100 mm VAS) at 1 week post treatment comparing the Cingal group and the Monovisc group,**

Data will be analyzed via an analysis of variance with a term for treatment and baseline pain score as a covariate. The primary hypothesis will be tested by a predefined contrast for comparing the Cingal group to the triamcinolone hexacetonide group. Formally, the hypothesis to be tested is:

$$H_0: \mu_{DC} = \mu_{DT} \text{ versus } H_A: \mu_{DC} \neq \mu_{DT}$$

Where  $\mu_{DC}$  is the mean change from baseline in the WOMAC Pain Score for the Cingal group at 1 week and  $\mu_{DT}$  is the mean change from baseline in the WOMAC Pain Score for the Monovisc group at 1 week. Since there are three treatment groups in this study, this hypothesis will be tested using a one way ANOVA and constructing a contrast for this hypothesis. This process of constructing a contrast is the same as using a two-sample t-test with the common variance estimate from the ANOVA.

This will be analyzed and tables like the primary endpoint in section 4.1.2.1.

#### **4.1.3.9 The usage of rescue medication through 26 weeks post treatment comparing the Cingal group to the triamcinolone hexacetonide group.**

Data will be analyzed via an analysis of variance (ANOVA) with a term for treatment. The primary hypothesis will be tested by a predefined contrast for comparing the Cingal group to the triamcinolone hexacetonide group. Formally, the hypothesis to be tested is:

$$H_0: \mu_{DC} = \mu_{DT} \text{ versus } H_A: \mu_{DC} \neq \mu_{DT}.$$

Where  $\mu_{DC}$  is the mean Number of Rescue Medications for the Cingal group at 26 weeks and  $\mu_{DT}$  is the mean Number of Rescue Medications for the triamcinolone hexacetonide group at 26 weeks. Since there are three treatment groups in this study, this hypothesis will be tested using a one way ANOVA and constructing a contrast for this hypothesis. This process is the same as using a two-sample t-test with the common variance estimate from the ANOVA.

This will be analyzed and tables like the primary endpoint in section 4.1.2.1.

#### **4.1.4 Exploratory Endpoints**

Any comparisons between groups (Cingal, Monovisc, TH), within groups and / or time points (from baseline through to 26 weeks) not described in the primary or secondary endpoints may be presented in the exploratory endpoints including:

- EuroQoL (EQ-5D)
- WOMAC Pain Score (100mm VAS)
- OMERACT-OARSI
- Total WOMAC
- WOMAC Stiffness Score

- WOMAC Physical Function Score
- Patient Global Assessment
- Evaluator Global Assessment
- Range of Motion
- Rescue Medication Usage: Difference in analgesic use measured by number of pills taken between visits will be compared between treatment groups descriptively.
- Number of Subjects Considered Treatment Failures: Treatment Failure: A subject who undergoes a procedure or uses a medication (other than the rescue medication) for the treatment of OA in the index knee at any time after the study injection through the 12 week visit.

For the exploratory analyses, the continuous variables will be analyzed via an analysis of variance and contrasts used to assess the prescribed comparisons. For the discrete variables, a Fisher's exact test will be used to assess the desired comparisons.

## *4.2 STATISTICAL METHODS*

Tabulation of summary statistics, graphical presentations, and statistical analyses will be performed using SAS<sup>®</sup> software 9.1.3 or higher version. Where not otherwise specified, the last pre-treatment observation will be used as baseline for calculating post-treatment changes from baseline. The primary presentations and analyses will be based on data pooled across study centers. Relevant summaries for individual centers, or combinations of centers, may be presented for primary data. All testing and confidence intervals will use a significance level of 5%.

## *4.3 DEMOGRAPHIC AND BASELINE CHARACTERISTICS*

All demographic and baseline characteristics will be tabulated by treatment group and a test of homogeneity between the treatment groups will be conducted. For continuous variables (e.g. age, height, weight) a one way ANOVA will be used. For categorical variables (e.g. gender, race), a Fisher's exact test or chi-squared test will be used. Medical history findings, physical examinations and concomitant medications will be tabulated by treatment group.

The baseline Chemistry, Hematology, Urinalysis, Vital Signs, and BMI data will be summarized via descriptive statistics and tested for homogeneity using a one way ANOVA.

## *4.4 ADVERSE EVENTS*

All AEs will be coded according to MedDRA. Safety assessments will include Treatment-Emergent Adverse Events (TEAEs) which are defined as AEs with an Investigator assessment of definitely, probably, or possibly related to CTM. TEAEs will be summarized with frequencies and percentages by system organ class and preferred term, severity, and relationship to study CTM for each treatment group. In summaries of TEAEs by severity and relationship to CTM for subjects reporting multiple episodes, all reported events will be included, not only the worst reported case. Serious Adverse Events will also be presented by relationship to the CTM.

The number of subjects with at least one AE will be tabulated for each treatment group. Differences between the treatment groups will be tested using Fisher's exact test. Then the number of AEs for each treatment group will also be tabulated.

The number of subjects and the number of AEs will be tabulated by severity, relationship, and local injection site specific events versus non local events.

#### *4.5 SUBJECT POPULATIONS*

All safety analyses will be conducted on all subjects who undergo treatment in any group.

The primary analysis on the primary endpoint will be performed on the ITT populations using the Multiple Imputation Methodology. The Multiple Imputation Methodology will use a mixed effects repeated measures model to predict the missing values. All Primary and Secondary endpoints will be analyzed using the ITT population.

It has been determined that any missing data in this study will follow the Missing at Random (MAR) assumption and is justified by the following section from the guide on missing data.

**Missing Data Because of Attrition in the Course of the Study** The longer the planned length of a clinical trial, the greater the chance that participants will drop out of the trial due to their moving out of the area or otherwise experiencing changes in their lives that preclude or complicate further participation. If dropping out due to these situations is known to be unrelated to changes in health status, an MAR assumption for the missing values seems justified;

Since none of these patients are likely to be in a life threatening disease situation and many have had knee pain for a period of time, the missing data will unlikely be due to any treatment effect or lack thereof. Previous studies have demonstrated a missing data rate of less than 1%. Thus, any missing data in this study follows that paradigm and thus should be considered MAR. Under this MAR assumption, the mixed effects repeated measures analysis yields unbiased estimates of the treatment effects and thus will be utilized in the analysis.

A secondary analysis will be conducted on the Per Protocol (PP) population. Since the primary endpoint is at 26 weeks, this is all subjects who complete the 26 week visit and who are not major violators of the protocol. For all other visits, this is defined as the subjects who complete those visits according to the protocol.

#### *4.6 ADDITIONAL ANALYSES*

All of the analyses are performed on the data with the specified covariates or other factors assumed in the model. If it is determined that certain factors may influence the outcomes of the endpoints, then additional analyses will be performed. For the continuous variables, the factors will be added to the ANOVA model and evaluated in a stepwise fashion for significance. For the discrete variables, the data will be analyzed via a GEE model with the factors added to the model.